These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 18996656)

  • 21. Association of hormone therapy and incident gout: population-based case-control study.
    Bruderer SG; Bodmer M; Jick SS; Meier CR
    Menopause; 2015 Dec; 22(12):1335-42. PubMed ID: 25968834
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Hormone replacement therapy and cardiovascular health in the United States.
    Shetty KD; Vogt WB; Bhattacharya J
    Med Care; 2009 May; 47(5):600-6. PubMed ID: 19319001
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Cancer issues.
    Marsden J; Sturdee D
    Best Pract Res Clin Obstet Gynaecol; 2009 Feb; 23(1):87-107. PubMed ID: 19036643
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hormone replacement therapy as a risk factor for non-small cell lung cancer: results of a case-control study.
    Ramnath N; Menezes RJ; Loewen G; Dua P; Eid F; Alkhaddo J; Paganelli G; Natarajan N; Reid ME
    Oncology; 2007; 73(5-6):305-10. PubMed ID: 18493157
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Estrogen-progestogen replacement therapy and ovarian cancer: an update.
    La Vecchia C
    Eur J Cancer Prev; 2006 Dec; 15(6):490-2. PubMed ID: 17106327
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Tibolone: clinical recommendations and practical guidelines. A report of the International Tibolone Consensus Group.
    Kenemans P; Speroff L;
    Maturitas; 2005 May; 51(1):21-8. PubMed ID: 15883105
    [TBL] [Abstract][Full Text] [Related]  

  • 27. No evidence for variation in colorectal cancer risk associated with different types of postmenopausal hormone therapy.
    Hoffmeister M; Raum E; Krtschil A; Chang-Claude J; Brenner H
    Clin Pharmacol Ther; 2009 Oct; 86(4):416-24. PubMed ID: 19606090
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Persistence with oral and transdermal hormone replacement therapy and hospitalisation for cardiovascular outcomes.
    Corrao G; Zambon A; Nicotra F; Fornari C; La Vecchia C; Mezzanzanica M; Nappi RE; Merlino L; Cesana G
    Maturitas; 2007 Jul; 57(3):315-24. PubMed ID: 17485182
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Tibolone and endometrial cancer: a cohort and nested case-control study in the UK.
    de Vries CS; Bromley SE; Thomas H; Farmer RD
    Drug Saf; 2005; 28(3):241-9. PubMed ID: 15733028
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Estrogen replacement and migraine.
    MacGregor EA
    Maturitas; 2009 May; 63(1):51-5. PubMed ID: 19375252
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The neurology of menopause.
    Henderson VW
    Neurologist; 2006 May; 12(3):149-59. PubMed ID: 16688016
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Myocardial infarction risk and hormone replacement: differences between products.
    de Vries CS; Bromley SE; Farmer RD
    Maturitas; 2006 Feb; 53(3):343-50. PubMed ID: 16040209
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Hormonal replacement therapy in menopause and cancer risk. An update].
    La Vecchia C; Franceschi S
    Minerva Ginecol; 2003 Jun; 55(3):217-9. PubMed ID: 14581867
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Effects of hormone replacement therapy on insulin resistance and platelet function tests.
    Saraç F; Saydam G; Sahin F; Oztekin K; Saygili F; Tüzün M; Yilmaz C
    Med Princ Pract; 2009; 18(1):43-7. PubMed ID: 19060490
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Hormone replacement therapy in women with systemic lupus erythematosus and risk of cardiovascular disease.
    Hochman J; Urowitz MB; Ibañez D; Gladman DD
    Lupus; 2009 Apr; 18(4):313-7. PubMed ID: 19276299
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Complexities of oestrogen in stroke.
    Carswell HV; Macrae IM; Farr TD
    Clin Sci (Lond); 2009 Dec; 118(6):375-89. PubMed ID: 20001955
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Postmenopausal Hormone Therapy and Risk of Stroke: Impact of the Route of Estrogen Administration and Type of Progestogen.
    Canonico M; Carcaillon L; Plu-Bureau G; Oger E; Singh-Manoux A; Tubert-Bitter P; Elbaz A; Scarabin PY
    Stroke; 2016 Jul; 47(7):1734-41. PubMed ID: 27256671
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Hormone replacement therapy and the risk of venous thromboembolism: a population-based study.
    Renoux C; Dell'Aniello S; Suissa S
    J Thromb Haemost; 2010 May; 8(5):979-86. PubMed ID: 20230416
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen and stroke: a review of the current literature.
    Carwile E; Wagner AK; Crago E; Alexander SA
    J Neurosci Nurs; 2009 Feb; 41(1):18-25; quiz 26-7. PubMed ID: 19368068
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Risk of ischemic stroke and lifetime estrogen exposure.
    Alonso de Leciñana M; Egido JA; Fernández C; Martínez-Vila E; Santos S; Morales A; Martínez E; Pareja A; Alvarez-Sabín J; Casado I;
    Neurology; 2007 Jan; 68(1):33-8. PubMed ID: 17200489
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.